Clinical Studies
-
Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer
Currently EnrollingVerdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.
Study Details -
Metabolomics Trial to Evaluate for Systemic Consequences of Intestinal Dysbiosis
Currently EnrollingThe intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog.
Study Details -
K9 Tumor And Blood Sampling for Osteosarcoma and Oral Melanoma (KABOOM)
Currently EnrollingNaturally occurring cancers in dogs have been as used as models for human cancers for many reasons; however, the genomic profiles of many of these cancers are still incompletely understood. Further definition of these genomic landscapes will allow for improved development of novel diagnostics and therapeutics to diagnose and treat these cancers. The objective of this
Study Details -
Tolerability of Oral Paclitaxel in Cancer-Bearing Dogs
ClosedResearch Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second
Study Details -
Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH)
Currently EnrollingEthos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.
Study Details -
Diet to replace Insulin Administration as a Better and Effective Treatment In Clinical (DIABETIC) Cats
Currently EnrollingA new cat diet has been shown to reduce body fat while maintaining lean muscle mass in cats. Accordingly, the following clinical study now seeks to determine if feeding this new diet without concurrent insulin therapy can induce insulin remission in cats with diabetes.
Study Details -
Diet to complement Insulin Administration as a Better and Effective Treatment In Clinical (DIABETIC) Dogs
ClosedThis clinical study seeks to determine if feeding the new diet in combination with insulin can improve glycemic control in dogs with moderately controlled diabetes.
Study Details -
Collection of Biological Specimens from Dogs Scheduled for Biopsy or Surgery for Suspected or Known Cancer
ClosedThis study will compare certain markers in the blood that are specific to cancer, but not found in healthy dogs, before and after surgical biopsy or surgical removal of a mass.
Study Details -
Collection of Biological Specimens from Dogs Diagnosed with Cancer, but Not Scheduled to Undergo Surgery for Tumor Removal
No Longer EnrollingThis study will compare markers in the blood that are specific to cancer but not found in healthy dogs, before and after treatment for cancer has begun.
Study Details -
Dysbiosis Enhancing Linkage Towards Association with Canine Osteosarcoma (DEL-TACO Lite)
Currently EnrollingIntestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.
Study Details